| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | Itm2a |
| Uniprot No | Q61500 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 1-263aa |
| 氨基酸序列 | MVKIAFNTPTAVQKEEARQDVEALVSRTVRAQILTGKELRVVPQEKDGSSGRCMLTLLGLSFILAGLIVGGACIYKYFMPKSTIYHGEMCFFDSEDPVNSIPGGEPYFLPVTEEADIREDDNIAIIDVPVPSFSDSDPAAIIHDFEKGMTAYLDLLLGNCYLMPLNTSIVMTPKNLVELFGKLASGKYLPHTYVVREDLVAVEEIRDVSNLGIFIYQLCNNRKSFRLRRRDLLLGFNKRAIDKCWKIRHFPNEFIVETKICQE |
| 预测分子量 | 31.2 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是3篇关于ITM2A重组蛋白的参考文献及其简要摘要：
1. **"ITM2A regulates bone development by modulating chondrocyte differentiation"**
*作者：Kwan, T., et al. (2015), Journal of Biological Chemistry*
摘要：研究通过重组ITM2A蛋白发现其能抑制软骨细胞分化，影响骨骼发育，并揭示其通过BMP信号通路调控这一过程。
2. **"ITM2A interacts with BRI2 and modulates amyloid-β peptide production"**
*作者：Tominaga, A., et al. (2007), Biochemical and Biophysical Research Communications*
摘要：利用重组ITM2A蛋白证实其与阿尔茨海默病相关蛋白BRI2的结合，可能通过调节γ-分泌酶活性减少β-淀粉样蛋白生成。
3. **"ITM2A promotes mesenchymal stem cell osteogenesis via Wnt/β-catenin signaling"**
*作者：Hsu, S.H., et al. (2018), Stem Cell Research & Therapy*
摘要：重组ITM2A蛋白处理间充质干细胞可激活Wnt通路，增强成骨分化，提示其在骨再生治疗中的潜在应用。
4. **"Structural insights into ITM2A extracellular domain oligomerization"**
*作者：Chen, Y., et al. (2020), Biochimica et Biophysica Acta (BBA) - Proteins and Proteomics*
摘要：通过重组ITM2A胞外域的结构分析，揭示其通过特定结构域形成寡聚体，影响其在细胞表面的功能。
(注：上述文献为示例，实际引用需根据具体研究验证)
**Background of ITM2A Recombinant Protein**
ITM2A (Integral Membrane Protein 2A) is a member of the ITM2 family, which comprises type II transmembrane proteins characterized by a conserved BRICHOS domain in their extracellular region. Primarily expressed in skeletal tissues, ITM2A plays roles in chondrogenesis, cellular differentiation, and apoptosis regulation. Its structure includes a short N-terminal cytoplasmic tail, a transmembrane domain, and a C-terminal extracellular BRICHOS domain, which is implicated in protein-protein interactions and chaperone-like functions, potentially mitigating amyloid fibril formation.
The recombinant ITM2A protein is engineered in vitro using expression systems like *E. coli* or mammalian cells, enabling high-purity production for functional studies. Research highlights its involvement in skeletal development, where it modulates BMP (bone morphogenetic protein) signaling and collagen maturation. Dysregulation of ITM2A is linked to diseases such as osteoarthritis, neurodegenerative disorders (e.g., Alzheimer’s disease, via interactions with amyloid-beta), and cancers, where it may act as a tumor suppressor.
As a recombinant protein, ITM2A serves as a tool to study its biological mechanisms, screen therapeutic agents, or explore its potential as a biomarker. Challenges remain in fully elucidating its multifunctional roles and signaling pathways, necessitating further structural and in vivo studies. Overall, ITM2A represents a promising target for understanding tissue homeostasis and developing therapies for related pathologies.
(Word count: 199)
*Note: The text is condensed to meet the 400-word limit while retaining key points.*
×
